Author: Dr Fouad Bitar

Boston, MA — October 2025 — Avigena, a U.S.-based genomic medicine company, officially
launched its Boston office in October 2025, marking a key milestone in its global expansion.
The launch took place in the presence of Avigena Co-Founders Fadi Bitar and Akl Fahed.
Through its Boston hub, Avigena aims to introduce advanced genomic prediction and prevention
services to the Middle East and North Africa (MENA) region, while building sustainable
programs that strengthen healthcare systems and improve the health and lives of people across
the region.
Avigena’s mission is to empower individuals and healthcare professionals with accurate,
accessible, and actionable genomic insights to support informed decisions in health, wellness,
and disease prevention.

Boston, MA — November 2025 — Avigena, a U.S.-based genomic medicine company, has
entered a landmark collaboration with the Laboratory for Molecular Medicine (LMM) at
Mass General Brigham, marking the first introduction of advanced predictive and preventive
genomic testing tailored to Middle East and North Africa (MENA) populations.
Through this partnership, Avigena will deploy LMM’s state-of-the-art genomic technologies to
enable earlier risk prediction, precision prevention, and scalable population health impact across
the region.

The agreement was finalized during a strategic visit to Boston, where Avigena Co-Founders
Fadi Bitar and Akl Fahed met with Matthew Lebo, Chief Laboratory Director of LMM and
Harvard Medical School faculty, and Lisa Marie Mahanta, Director of Clinical Operations at
LMM.

The collaboration underscores a shared mission to expand access to world-class genomic science
and advance precision prevention across the MENA region.

Under the umbrella of Saudi Arabia’s National Biotechnology Strategy and as part of the high-
level MoU signings at the Saudi Pavilion during the BIO International Convention 2025 in
Boston, Massachusetts, Novo Genomics and Avigena signed a landmark Memorandum of
Understanding (MoU) on June 16, 2025.

This agreement reflects the Kingdom’s bold commitment to global collaboration and innovation-driven healthcare transformation. The MoU marks a strategic partnership between Avigena, a U.S.-based genomic medicine
company specializing in polygenic risk scores (PRS) and preventive health solutions, and Novo
Genomics, a Saudi Arabian biotechnology leader in genomics, multi-omics, and precision
medicine. Together, the two companies will collaborate to deliver cutting-edge genomic testing
and personalized health services tailored for Arab populations, focusing on cardiovascular
disease, cancer, and diabetes risk prediction.